A5057673105- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Organ Transplantation Techniques and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Drug-Induced Hepatotoxicity and Protection
- Renal Transplantation Outcomes and Treatments
- Viral-associated cancers and disorders
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
- Hepatitis B Virus Studies
- Liver Diseases and Immunity
- Alcohol Consumption and Health Effects
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Hepatitis Viruses Studies and Epidemiology
- Metabolism and Genetic Disorders
- Adolescent and Pediatric Healthcare
- Transplantation: Methods and Outcomes
- Electrolyte and hormonal disorders
- Extracellular vesicles in disease
- Venous Thromboembolism Diagnosis and Management
- Nutrition and Health in Aging
- Hormonal Regulation and Hypertension
- Cancer Mechanisms and Therapy
- Inflammatory Biomarkers in Disease Prognosis
Universitat de Barcelona
2023-2024
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2023-2024
University of Padua
2016-2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2023-2024
Centre for Biomedical Network Research on Rare Diseases
2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2023-2024
Fundació Clínic per a la Recerca Biomèdica
2024
Centro de Investigación Biomédica en Red
2023
Agència de Gestió d'Ajuts Universitaris i de Recerca
2023
ERN GUARD-Heart
2023
Bacterial infections in cirrhosis are associated with increased bleeding risk. To assess the factors responsible for tendency patients bacterial infections, we conducted a prospective study comparing all 3 aspects of hemostasis (platelets, coagulation, and fibrinolysis) hospitalized decompensated vs. without infections.Primary assessment included whole blood platelet aggregation von Willebrand factor (VWF). Coagulation procoagulant (fibrinogen, II, V, VII, VIII, IX, X, XI, XII, XIII),...
Background and objective Portal vein thrombosis (PVT) is a common complication in cirrhosis, when complete, it increases morbidity mortality liver transplant candidates. The aim of the study was to assess hemostatic status, as well clinical characteristics thrombus patients, predictors therapeutic efficacy anticoagulation for treatment PVT cirrhotics. Patients methods with cirrhosis consecutively treated enoxaparin were enrolled. All patients underwent evaluation coagulation status...
Abstract Background Portal vein thrombosis (PVT) is the most common thrombotic complication in cirrhosis; however, local risk factors involved its pathogenesis are still not fully investigated. The aim of study was to evaluate hemostasis and endothelial damage portal patients with cirrhosis hypertension. Methods Adult cirrhotics undergoing transjugular intrahepatic portosystemic shunt were consecutively enrolled. Rotational thromboelastometry (ROTEM), dosage total circulating...
Concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following direct-acting antiviral (DAA) therapy in patients with cirrhosis a prior complete oncological response have been raised. Data regarding the impact of HCV treatment DAAs on wait-list dropout rates active HCC and HCV-related awaiting liver transplantation (LT) are lacking. HCV-HCC listed for LT between January 2015 May 2016 at Padua Liver Transplant Center were considered eligible study. After enrollment,...
Abstract Background Extracellular vesicles (EVs) modulate inflammation, coagulation and vascular homeostasis in decompensated cirrhosis. Aim To characterize the profile of plasmatic EVs patients with cirrhosis bacterial infections evaluate association between development hemostatic complications. Methods We measured levels using high‐sensitivity flow cytometry phospholipid‐dependent clotting time (PPL) a prospective cohort hospitalized acutely versus without infections. A separate was also...
Hepatocellular carcinoma (HCC) in patients with decompensated cirrhosis presents significant treatment challenges due to the impaired liver function, altered pharmacokinetics, and systemic inflammation associated advanced disease. This review explores complexities of managing HCC this high-risk population, focusing on pharmacological considerations impact drug metabolism, efficacy, adverse effects. Studies indicate that drugs metabolized by liver, such as tyrosine kinase inhibitors (TKIs)...
The long-term impact of sustained virological response (SVR) after direct-acting antivirals (DAAs) on the hypercoagulability associated with HCV cirrhosis is unknown. We longitudinally evaluated effect DAAs treatment cirrhotic coagulopathy.Pro- and anticoagulant factor levels thrombin generation were assessed in patients HCV-related at baseline, end therapy (EOT), 12, 24 48 weeks (W) EOT.Fifty-eight enrolled (86% Child's A). SVR was 100%. Median VIII activity significantly decreased EOT, 12...
Hyper-functional platelets are being proposed as a potential therapeutic target in multiple cancers. Whether this can be considered patients with cirrhosis and hepatocellular carcinoma (HCC) is unknown their platelet function has not yet been investigated. We evaluated HCC. Patients without HCC were prospectively recruited. Platelet aggregation, marker of function, was assessed by impedance aggregometry adenosine diphosphate (ADP), arachidonic acid (ASPI), thrombin (TRAP) stimulation....
To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals (DAAs).All adult listed for LT at Padua University Hospital between 2006-2017 were retrospectively collected using a prospectively-updated database; HCV-related divided by indication [dec-HCV vs HCV/ hepatocellular carcinoma (HCC)] into two interval times (2006-2013 2014-2017) according to DAAs. For each...
In the setting of liver transplant (LT), survival after diagnosis de novo malignancies (DNMs) has been poorly investigated. this study, we assessed impact DNMs on LT recipients as compared to corresponding without DNM. A nested case-control study was conducted in a cohort 2,818 enrolled nine Italian centres between 1985 and 2014. Cases were 244 who developed LT. For each case, two controls matched for gender, age, year at selected by incidence density sampling among members The probabilities...
In patients with cirrhosis, particularly those hepatocellular carcinoma (HCC), hypercoagulability may be associated purported increased risks of portal vein thrombosis and cirrhosis progression. this study, we extensively investigated hemostatic alterations potentially responsible for the thrombotic tendency in HCC, evaluated whether such were predictive hepatic decompensation. Patients at all stages prospectively recruited underwent an extensive assessment, including procoagulant factors...
Transjugular intrahepatic portosystemic shunt (TIPS) emerges as a key treatment for portal hypertension (PH) complications. While international guidelines provide clear indications its use in cirrhosis, empirical knowledge is notably scarcer non-cirrhotic PH, particularly nonmalignant noncirrhotic vein thrombosis (NNPVT) and patients with portosinusoidal vascular disorder (PSVD). Patients afflicted by these rare diseases exhibit distinct clinical profiles compared to their cirrhotic...
This cohort study assessed, in Italy, the overall pattern of risk de novo malignancies following liver transplantation (LT). The group included 2,832 individuals who underwent LT between 1985 and 2014 nine centers all over Italy. Person–years (PYs) at cancer were computed from 30 days after to date diagnosis, death or end follow‐up. Excess risk, as compared general population, was estimated using standardized incidence ratios (SIRs) 95% confidence intervals (CIs). During 18,642 PYs, 246...
Background and Aims: HCC can increase the risk of nonneoplastic PVT in cirrhosis. However, natural history its prognostic role patients are unknown. Approach Results: Consecutive with cirrhosis undergoing laparoscopic ablation were retrospectively evaluated followed up to 36 months. characteristics evolution reviewed. was categorized according lumen occupancy (≤50%, >50% <100%, = 100%) extension other veins. The thrombosis considered at 1 year from diagnosis. Variables associated...